PSMA PET/CT的使用改善接受挽救性放疗的生化复发前列腺癌男性的总生存:来自全国范围的真实世界数据
该研究基于丹麦2015至2023年全国真实世界数据,纳入844例根治性前列腺切除术后生化复发且PSA 0.2-1.0 ng/mL、接受挽救性放疗的患者,其中308例(36.5%)在放疗前接受了PSMA PET/CT。结果显示,接受PSMA PET/CT的患者总生存期和生化复发无生存期均优于未接受者。
要点
- 放疗前接受PSMA PET/CT的患者5年总生存率为98.1%,未接受者为93.8%。
- PSMA PET/CT组3年生化复发无生存率为74.9%,未接受组为69.4%。
- 放疗前PSMA PET/CT的使用与改善的总生存和生化复发无生存相关。
核心结论
- 挽救性放疗前使用PSMA PET/CT与改善的总生存和生化复发无生存相关。
研究设计与样本
- 本研究使用丹麦2015年至2023年所有接受挽救性放疗患者的常规临床实践真实世界数据。
- 患者根据是否在治疗前接受PSMA PET/CT进行分组,仅纳入前列腺特异性抗原值为0.2-1.0 ng/mL的患者。
- 主要目标是比较挽救性放疗完成后至多5年的总生存,生化复发无生存作为次要结局。
主要发现
- 共844例患者接受挽救性放疗,其中308例(36.5%)在治疗前接受了PSMA PET/CT。
- PSMA PET/CT组1年、2年、5年生存率分别为100%(95%CI,100%-100%)、99.5%(95%CI,98.6%-100%)、98.1%(95%CI,96%-100%)。
- 非PSMA PET/CT组1年、2年、5年生存率分别为99%(95%CI,98.2%-99.9%)、97.8%(95%CI,96.5%-99.1%)、93.8%(95%CI,91.5%-96.2%)。
- 粗风险比为3.31(95%CI,1.01-10.88;P=0.0486),PSMA PET/CT组总生存优于非PSMA PET/CT组。
- 3年生化复发无生存率在PSMA PET/CT组为74.9%(95%CI,68.5%-81.3%),非PSMA PET/CT组为69.4%(95%CI,65.2%-73.7%),风险比为1.53(95%CI,1.07-2.19;P=0.0187)。
临床怎么用
- 国际指南推荐将挽救性放疗作为根治性前列腺切除术后生化复发男性的治愈性治疗。
- PSMA PET/CT在低前列腺特异性抗原水平下对复发灶定位具有高灵敏度,可改善治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
International guidelines recommend salvage radiotherapy (sRT) as a curative treatment for men with biochemically recurrent prostate cancer after radical prostatectomy. Prostate-specific membrane antigen (PSMA) PET/CT has demonstrated high sensitivity for localizing recurrent disease at low prostate-specific antigen levels, enabling improved treatment decision-making. However, few studies have investigated the impact of pre-sRT PSMA PET/CT on patient-relevant outcomes, that is, recurrence-free and overall survival. Moreover, no comparison exists of overall survival between patients who underwent PSMA PET/CT and those who did not, before sRT. Methods: This study used real-world data (obtained from routine clinical practice) of all patients treated with sRT in Denmark from 2015 through 2023. Patients were categorized according to whether they underwent pretreatment PSMA PET/CT. Our main objective was to compare overall survival up to 5 y after completion of sRT. Biochemical recurrence-free survival (BRFS) was included as a secondary outcome. Only patients with a prostate-specific antigen value of 0.2-1.0 ng/mL were included. Results: In total, 844 patients were treated with sRT during the study period, of whom 308 (36.5%) underwent pretreatment PSMA PET/CT. The analysis revealed greater overall survival for patients who underwent PSMA PET/CT before sRT than for patients who did not. The 1-, 2-, and 5-y survival rates for PSMA PET/CT patients were 100% (95% CI, 100%-100%), 99.5% (95% CI, 98.6%-100%), and 98.1% (95% CI, 96%-100%), respectively, versus 99% (95% CI, 98.2%-99.9%), 97.8% (95% CI, 96.5%-99.1%), and 93.8% (95% CI, 91.5%-96.2%), respectively, for non-PSMA PET/CT patients (crude hazard ratio, 3.31 [95% CI, 1.01-10.88]; P = 0.0486). Comparatively, the 3-y BRFS rate was consistent with overall survival: 74.9% (95% CI, 68.5%-81.3%) for PSMA PET/CT patients and 69.4% (95% CI, 65.2%-73.7%) for non-PSMA PET/CT patients, with a hazard ratio of 1.53 (95% CI, 1.07-2.19; P = 0.0187). Conclusion: PSMA PET/CT use before sRT was associated with improved overall survival and BRFS.
引用
- Mogensen AW, Torp-Pedersen C, Nørgaard M, et al. The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from an Entire Country. J Nucl Med. 2025. PMID: 40506242. doi:10.2967/jnumed.125.269996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。